Global Measurable Residual Disease Testing Supply, Demand and Key Producers, 2023-2029
The global Measurable Residual Disease Testing market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
Measurable residual disease (also known as “minimal residual disease”) refers to the number of cancer cells that remain during and after cancer treatment. Complete remission (less than 5% blasts in bone marrow) by morphologic assessment is not enough to accurately depict remaining malignant cells.
This report studies the global Measurable Residual Disease Testing demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Measurable Residual Disease Testing, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Measurable Residual Disease Testing that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Measurable Residual Disease Testing total market, 2018-2029, (USD Million)
Global Measurable Residual Disease Testing total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Measurable Residual Disease Testing total market, key domestic companies and share, (USD Million)
Global Measurable Residual Disease Testing revenue by player and market share 2018-2023, (USD Million)
Global Measurable Residual Disease Testing total market by Type, CAGR, 2018-2029, (USD Million)
Global Measurable Residual Disease Testing total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Measurable Residual Disease Testing market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Adaptive Biotechnologies Corporation, ArcherDX, Inc. (Invitae Corporation), Asuragen, Arup Laboratories, Bio-Rad Laboratories, Cergentis B.V., F. Hoffmann- La Roche Ltd, Guardant Health and ICON plc, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Measurable Residual Disease Testing market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Measurable Residual Disease Testing Market, By Region:
1. How big is the global Measurable Residual Disease Testing market?
2. What is the demand of the global Measurable Residual Disease Testing market?
3. What is the year over year growth of the global Measurable Residual Disease Testing market?
4. What is the total value of the global Measurable Residual Disease Testing market?
5. Who are the major players in the global Measurable Residual Disease Testing market?
6. What are the growth factors driving the market demand?
Measurable residual disease (also known as “minimal residual disease”) refers to the number of cancer cells that remain during and after cancer treatment. Complete remission (less than 5% blasts in bone marrow) by morphologic assessment is not enough to accurately depict remaining malignant cells.
This report studies the global Measurable Residual Disease Testing demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Measurable Residual Disease Testing, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Measurable Residual Disease Testing that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Measurable Residual Disease Testing total market, 2018-2029, (USD Million)
Global Measurable Residual Disease Testing total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Measurable Residual Disease Testing total market, key domestic companies and share, (USD Million)
Global Measurable Residual Disease Testing revenue by player and market share 2018-2023, (USD Million)
Global Measurable Residual Disease Testing total market by Type, CAGR, 2018-2029, (USD Million)
Global Measurable Residual Disease Testing total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Measurable Residual Disease Testing market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Adaptive Biotechnologies Corporation, ArcherDX, Inc. (Invitae Corporation), Asuragen, Arup Laboratories, Bio-Rad Laboratories, Cergentis B.V., F. Hoffmann- La Roche Ltd, Guardant Health and ICON plc, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Measurable Residual Disease Testing market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Measurable Residual Disease Testing Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Flow Cytometry
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Other
- Hematological Malignancies
- Leukemia
- Lymphoma
- Solid Tumors
- Other
- Adaptive Biotechnologies Corporation
- ArcherDX, Inc. (Invitae Corporation)
- Asuragen
- Arup Laboratories
- Bio-Rad Laboratories
- Cergentis B.V.
- F. Hoffmann- La Roche Ltd
- Guardant Health
- ICON plc
- Invivoscribe
- Laboratory Corporation of America Holdings
- Mission Bio
- Natera, Inc.
- NeoGenomics Laboratories
- Opko Health
- Quest Diagnostics Incorporated
- Sysmex Corporation
- Genetron Health
1. How big is the global Measurable Residual Disease Testing market?
2. What is the demand of the global Measurable Residual Disease Testing market?
3. What is the year over year growth of the global Measurable Residual Disease Testing market?
4. What is the total value of the global Measurable Residual Disease Testing market?
5. Who are the major players in the global Measurable Residual Disease Testing market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Measurable Residual Disease Testing Introduction
1.2 World Measurable Residual Disease Testing Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Measurable Residual Disease Testing Total Market by Region (by Headquarter Location)
1.3.1 World Measurable Residual Disease Testing Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Measurable Residual Disease Testing Market Size (2018-2029)
1.3.3 China Measurable Residual Disease Testing Market Size (2018-2029)
1.3.4 Europe Measurable Residual Disease Testing Market Size (2018-2029)
1.3.5 Japan Measurable Residual Disease Testing Market Size (2018-2029)
1.3.6 South Korea Measurable Residual Disease Testing Market Size (2018-2029)
1.3.7 ASEAN Measurable Residual Disease Testing Market Size (2018-2029)
1.3.8 India Measurable Residual Disease Testing Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Measurable Residual Disease Testing Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Measurable Residual Disease Testing Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Measurable Residual Disease Testing Consumption Value (2018-2029)
2.2 World Measurable Residual Disease Testing Consumption Value by Region
2.2.1 World Measurable Residual Disease Testing Consumption Value by Region (2018-2023)
2.2.2 World Measurable Residual Disease Testing Consumption Value Forecast by Region (2024-2029)
2.3 United States Measurable Residual Disease Testing Consumption Value (2018-2029)
2.4 China Measurable Residual Disease Testing Consumption Value (2018-2029)
2.5 Europe Measurable Residual Disease Testing Consumption Value (2018-2029)
2.6 Japan Measurable Residual Disease Testing Consumption Value (2018-2029)
2.7 South Korea Measurable Residual Disease Testing Consumption Value (2018-2029)
2.8 ASEAN Measurable Residual Disease Testing Consumption Value (2018-2029)
2.9 India Measurable Residual Disease Testing Consumption Value (2018-2029)
3 WORLD MEASURABLE RESIDUAL DISEASE TESTING COMPANIES COMPETITIVE ANALYSIS
3.1 World Measurable Residual Disease Testing Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Measurable Residual Disease Testing Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Measurable Residual Disease Testing in 2022
3.2.3 Global Concentration Ratios (CR8) for Measurable Residual Disease Testing in 2022
3.3 Measurable Residual Disease Testing Company Evaluation Quadrant
3.4 Measurable Residual Disease Testing Market: Overall Company Footprint Analysis
3.4.1 Measurable Residual Disease Testing Market: Region Footprint
3.4.2 Measurable Residual Disease Testing Market: Company Product Type Footprint
3.4.3 Measurable Residual Disease Testing Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Measurable Residual Disease Testing Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Measurable Residual Disease Testing Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Measurable Residual Disease Testing Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Measurable Residual Disease Testing Consumption Value Comparison
4.2.1 United States VS China: Measurable Residual Disease Testing Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Measurable Residual Disease Testing Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Measurable Residual Disease Testing Companies and Market Share, 2018-2023
4.3.1 United States Based Measurable Residual Disease Testing Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Measurable Residual Disease Testing Revenue, (2018-2023)
4.4 China Based Companies Measurable Residual Disease Testing Revenue and Market Share, 2018-2023
4.4.1 China Based Measurable Residual Disease Testing Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Measurable Residual Disease Testing Revenue, (2018-2023)
4.5 Rest of World Based Measurable Residual Disease Testing Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Measurable Residual Disease Testing Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Measurable Residual Disease Testing Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Measurable Residual Disease Testing Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Flow Cytometry
5.2.2 Polymerase Chain Reaction (PCR)
5.2.3 Next-Generation Sequencing (NGS)
5.2.4 Other
5.3 Market Segment by Type
5.3.1 World Measurable Residual Disease Testing Market Size by Type (2018-2023)
5.3.2 World Measurable Residual Disease Testing Market Size by Type (2024-2029)
5.3.3 World Measurable Residual Disease Testing Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Measurable Residual Disease Testing Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hematological Malignancies
6.2.2 Leukemia
6.2.3 Lymphoma
6.2.4 Solid Tumors
6.2.5 Solid Tumors
6.3 Market Segment by Application
6.3.1 World Measurable Residual Disease Testing Market Size by Application (2018-2023)
6.3.2 World Measurable Residual Disease Testing Market Size by Application (2024-2029)
6.3.3 World Measurable Residual Disease Testing Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Adaptive Biotechnologies Corporation
7.1.1 Adaptive Biotechnologies Corporation Details
7.1.2 Adaptive Biotechnologies Corporation Major Business
7.1.3 Adaptive Biotechnologies Corporation Measurable Residual Disease Testing Product and Services
7.1.4 Adaptive Biotechnologies Corporation Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Adaptive Biotechnologies Corporation Recent Developments/Updates
7.1.6 Adaptive Biotechnologies Corporation Competitive Strengths & Weaknesses
7.2 ArcherDX, Inc. (Invitae Corporation)
7.2.1 ArcherDX, Inc. (Invitae Corporation) Details
7.2.2 ArcherDX, Inc. (Invitae Corporation) Major Business
7.2.3 ArcherDX, Inc. (Invitae Corporation) Measurable Residual Disease Testing Product and Services
7.2.4 ArcherDX, Inc. (Invitae Corporation) Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 ArcherDX, Inc. (Invitae Corporation) Recent Developments/Updates
7.2.6 ArcherDX, Inc. (Invitae Corporation) Competitive Strengths & Weaknesses
7.3 Asuragen
7.3.1 Asuragen Details
7.3.2 Asuragen Major Business
7.3.3 Asuragen Measurable Residual Disease Testing Product and Services
7.3.4 Asuragen Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Asuragen Recent Developments/Updates
7.3.6 Asuragen Competitive Strengths & Weaknesses
7.4 Arup Laboratories
7.4.1 Arup Laboratories Details
7.4.2 Arup Laboratories Major Business
7.4.3 Arup Laboratories Measurable Residual Disease Testing Product and Services
7.4.4 Arup Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Arup Laboratories Recent Developments/Updates
7.4.6 Arup Laboratories Competitive Strengths & Weaknesses
7.5 Bio-Rad Laboratories
7.5.1 Bio-Rad Laboratories Details
7.5.2 Bio-Rad Laboratories Major Business
7.5.3 Bio-Rad Laboratories Measurable Residual Disease Testing Product and Services
7.5.4 Bio-Rad Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Bio-Rad Laboratories Recent Developments/Updates
7.5.6 Bio-Rad Laboratories Competitive Strengths & Weaknesses
7.6 Cergentis B.V.
7.6.1 Cergentis B.V. Details
7.6.2 Cergentis B.V. Major Business
7.6.3 Cergentis B.V. Measurable Residual Disease Testing Product and Services
7.6.4 Cergentis B.V. Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Cergentis B.V. Recent Developments/Updates
7.6.6 Cergentis B.V. Competitive Strengths & Weaknesses
7.7 F. Hoffmann- La Roche Ltd
7.7.1 F. Hoffmann- La Roche Ltd Details
7.7.2 F. Hoffmann- La Roche Ltd Major Business
7.7.3 F. Hoffmann- La Roche Ltd Measurable Residual Disease Testing Product and Services
7.7.4 F. Hoffmann- La Roche Ltd Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 F. Hoffmann- La Roche Ltd Recent Developments/Updates
7.7.6 F. Hoffmann- La Roche Ltd Competitive Strengths & Weaknesses
7.8 Guardant Health
7.8.1 Guardant Health Details
7.8.2 Guardant Health Major Business
7.8.3 Guardant Health Measurable Residual Disease Testing Product and Services
7.8.4 Guardant Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Guardant Health Recent Developments/Updates
7.8.6 Guardant Health Competitive Strengths & Weaknesses
7.9 ICON plc
7.9.1 ICON plc Details
7.9.2 ICON plc Major Business
7.9.3 ICON plc Measurable Residual Disease Testing Product and Services
7.9.4 ICON plc Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 ICON plc Recent Developments/Updates
7.9.6 ICON plc Competitive Strengths & Weaknesses
7.10 Invivoscribe
7.10.1 Invivoscribe Details
7.10.2 Invivoscribe Major Business
7.10.3 Invivoscribe Measurable Residual Disease Testing Product and Services
7.10.4 Invivoscribe Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Invivoscribe Recent Developments/Updates
7.10.6 Invivoscribe Competitive Strengths & Weaknesses
7.11 Laboratory Corporation of America Holdings
7.11.1 Laboratory Corporation of America Holdings Details
7.11.2 Laboratory Corporation of America Holdings Major Business
7.11.3 Laboratory Corporation of America Holdings Measurable Residual Disease Testing Product and Services
7.11.4 Laboratory Corporation of America Holdings Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Laboratory Corporation of America Holdings Recent Developments/Updates
7.11.6 Laboratory Corporation of America Holdings Competitive Strengths & Weaknesses
7.12 Mission Bio
7.12.1 Mission Bio Details
7.12.2 Mission Bio Major Business
7.12.3 Mission Bio Measurable Residual Disease Testing Product and Services
7.12.4 Mission Bio Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Mission Bio Recent Developments/Updates
7.12.6 Mission Bio Competitive Strengths & Weaknesses
7.13 Natera, Inc.
7.13.1 Natera, Inc. Details
7.13.2 Natera, Inc. Major Business
7.13.3 Natera, Inc. Measurable Residual Disease Testing Product and Services
7.13.4 Natera, Inc. Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Natera, Inc. Recent Developments/Updates
7.13.6 Natera, Inc. Competitive Strengths & Weaknesses
7.14 NeoGenomics Laboratories
7.14.1 NeoGenomics Laboratories Details
7.14.2 NeoGenomics Laboratories Major Business
7.14.3 NeoGenomics Laboratories Measurable Residual Disease Testing Product and Services
7.14.4 NeoGenomics Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 NeoGenomics Laboratories Recent Developments/Updates
7.14.6 NeoGenomics Laboratories Competitive Strengths & Weaknesses
7.15 Opko Health
7.15.1 Opko Health Details
7.15.2 Opko Health Major Business
7.15.3 Opko Health Measurable Residual Disease Testing Product and Services
7.15.4 Opko Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Opko Health Recent Developments/Updates
7.15.6 Opko Health Competitive Strengths & Weaknesses
7.16 Quest Diagnostics Incorporated
7.16.1 Quest Diagnostics Incorporated Details
7.16.2 Quest Diagnostics Incorporated Major Business
7.16.3 Quest Diagnostics Incorporated Measurable Residual Disease Testing Product and Services
7.16.4 Quest Diagnostics Incorporated Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Quest Diagnostics Incorporated Recent Developments/Updates
7.16.6 Quest Diagnostics Incorporated Competitive Strengths & Weaknesses
7.17 Sysmex Corporation
7.17.1 Sysmex Corporation Details
7.17.2 Sysmex Corporation Major Business
7.17.3 Sysmex Corporation Measurable Residual Disease Testing Product and Services
7.17.4 Sysmex Corporation Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Sysmex Corporation Recent Developments/Updates
7.17.6 Sysmex Corporation Competitive Strengths & Weaknesses
7.18 Genetron Health
7.18.1 Genetron Health Details
7.18.2 Genetron Health Major Business
7.18.3 Genetron Health Measurable Residual Disease Testing Product and Services
7.18.4 Genetron Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.18.5 Genetron Health Recent Developments/Updates
7.18.6 Genetron Health Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Measurable Residual Disease Testing Industry Chain
8.2 Measurable Residual Disease Testing Upstream Analysis
8.3 Measurable Residual Disease Testing Midstream Analysis
8.4 Measurable Residual Disease Testing Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Measurable Residual Disease Testing Introduction
1.2 World Measurable Residual Disease Testing Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Measurable Residual Disease Testing Total Market by Region (by Headquarter Location)
1.3.1 World Measurable Residual Disease Testing Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Measurable Residual Disease Testing Market Size (2018-2029)
1.3.3 China Measurable Residual Disease Testing Market Size (2018-2029)
1.3.4 Europe Measurable Residual Disease Testing Market Size (2018-2029)
1.3.5 Japan Measurable Residual Disease Testing Market Size (2018-2029)
1.3.6 South Korea Measurable Residual Disease Testing Market Size (2018-2029)
1.3.7 ASEAN Measurable Residual Disease Testing Market Size (2018-2029)
1.3.8 India Measurable Residual Disease Testing Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Measurable Residual Disease Testing Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Measurable Residual Disease Testing Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Measurable Residual Disease Testing Consumption Value (2018-2029)
2.2 World Measurable Residual Disease Testing Consumption Value by Region
2.2.1 World Measurable Residual Disease Testing Consumption Value by Region (2018-2023)
2.2.2 World Measurable Residual Disease Testing Consumption Value Forecast by Region (2024-2029)
2.3 United States Measurable Residual Disease Testing Consumption Value (2018-2029)
2.4 China Measurable Residual Disease Testing Consumption Value (2018-2029)
2.5 Europe Measurable Residual Disease Testing Consumption Value (2018-2029)
2.6 Japan Measurable Residual Disease Testing Consumption Value (2018-2029)
2.7 South Korea Measurable Residual Disease Testing Consumption Value (2018-2029)
2.8 ASEAN Measurable Residual Disease Testing Consumption Value (2018-2029)
2.9 India Measurable Residual Disease Testing Consumption Value (2018-2029)
3 WORLD MEASURABLE RESIDUAL DISEASE TESTING COMPANIES COMPETITIVE ANALYSIS
3.1 World Measurable Residual Disease Testing Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Measurable Residual Disease Testing Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Measurable Residual Disease Testing in 2022
3.2.3 Global Concentration Ratios (CR8) for Measurable Residual Disease Testing in 2022
3.3 Measurable Residual Disease Testing Company Evaluation Quadrant
3.4 Measurable Residual Disease Testing Market: Overall Company Footprint Analysis
3.4.1 Measurable Residual Disease Testing Market: Region Footprint
3.4.2 Measurable Residual Disease Testing Market: Company Product Type Footprint
3.4.3 Measurable Residual Disease Testing Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Measurable Residual Disease Testing Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Measurable Residual Disease Testing Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Measurable Residual Disease Testing Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Measurable Residual Disease Testing Consumption Value Comparison
4.2.1 United States VS China: Measurable Residual Disease Testing Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Measurable Residual Disease Testing Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Measurable Residual Disease Testing Companies and Market Share, 2018-2023
4.3.1 United States Based Measurable Residual Disease Testing Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Measurable Residual Disease Testing Revenue, (2018-2023)
4.4 China Based Companies Measurable Residual Disease Testing Revenue and Market Share, 2018-2023
4.4.1 China Based Measurable Residual Disease Testing Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Measurable Residual Disease Testing Revenue, (2018-2023)
4.5 Rest of World Based Measurable Residual Disease Testing Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Measurable Residual Disease Testing Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Measurable Residual Disease Testing Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Measurable Residual Disease Testing Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Flow Cytometry
5.2.2 Polymerase Chain Reaction (PCR)
5.2.3 Next-Generation Sequencing (NGS)
5.2.4 Other
5.3 Market Segment by Type
5.3.1 World Measurable Residual Disease Testing Market Size by Type (2018-2023)
5.3.2 World Measurable Residual Disease Testing Market Size by Type (2024-2029)
5.3.3 World Measurable Residual Disease Testing Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Measurable Residual Disease Testing Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hematological Malignancies
6.2.2 Leukemia
6.2.3 Lymphoma
6.2.4 Solid Tumors
6.2.5 Solid Tumors
6.3 Market Segment by Application
6.3.1 World Measurable Residual Disease Testing Market Size by Application (2018-2023)
6.3.2 World Measurable Residual Disease Testing Market Size by Application (2024-2029)
6.3.3 World Measurable Residual Disease Testing Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Adaptive Biotechnologies Corporation
7.1.1 Adaptive Biotechnologies Corporation Details
7.1.2 Adaptive Biotechnologies Corporation Major Business
7.1.3 Adaptive Biotechnologies Corporation Measurable Residual Disease Testing Product and Services
7.1.4 Adaptive Biotechnologies Corporation Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Adaptive Biotechnologies Corporation Recent Developments/Updates
7.1.6 Adaptive Biotechnologies Corporation Competitive Strengths & Weaknesses
7.2 ArcherDX, Inc. (Invitae Corporation)
7.2.1 ArcherDX, Inc. (Invitae Corporation) Details
7.2.2 ArcherDX, Inc. (Invitae Corporation) Major Business
7.2.3 ArcherDX, Inc. (Invitae Corporation) Measurable Residual Disease Testing Product and Services
7.2.4 ArcherDX, Inc. (Invitae Corporation) Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 ArcherDX, Inc. (Invitae Corporation) Recent Developments/Updates
7.2.6 ArcherDX, Inc. (Invitae Corporation) Competitive Strengths & Weaknesses
7.3 Asuragen
7.3.1 Asuragen Details
7.3.2 Asuragen Major Business
7.3.3 Asuragen Measurable Residual Disease Testing Product and Services
7.3.4 Asuragen Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Asuragen Recent Developments/Updates
7.3.6 Asuragen Competitive Strengths & Weaknesses
7.4 Arup Laboratories
7.4.1 Arup Laboratories Details
7.4.2 Arup Laboratories Major Business
7.4.3 Arup Laboratories Measurable Residual Disease Testing Product and Services
7.4.4 Arup Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Arup Laboratories Recent Developments/Updates
7.4.6 Arup Laboratories Competitive Strengths & Weaknesses
7.5 Bio-Rad Laboratories
7.5.1 Bio-Rad Laboratories Details
7.5.2 Bio-Rad Laboratories Major Business
7.5.3 Bio-Rad Laboratories Measurable Residual Disease Testing Product and Services
7.5.4 Bio-Rad Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Bio-Rad Laboratories Recent Developments/Updates
7.5.6 Bio-Rad Laboratories Competitive Strengths & Weaknesses
7.6 Cergentis B.V.
7.6.1 Cergentis B.V. Details
7.6.2 Cergentis B.V. Major Business
7.6.3 Cergentis B.V. Measurable Residual Disease Testing Product and Services
7.6.4 Cergentis B.V. Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Cergentis B.V. Recent Developments/Updates
7.6.6 Cergentis B.V. Competitive Strengths & Weaknesses
7.7 F. Hoffmann- La Roche Ltd
7.7.1 F. Hoffmann- La Roche Ltd Details
7.7.2 F. Hoffmann- La Roche Ltd Major Business
7.7.3 F. Hoffmann- La Roche Ltd Measurable Residual Disease Testing Product and Services
7.7.4 F. Hoffmann- La Roche Ltd Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 F. Hoffmann- La Roche Ltd Recent Developments/Updates
7.7.6 F. Hoffmann- La Roche Ltd Competitive Strengths & Weaknesses
7.8 Guardant Health
7.8.1 Guardant Health Details
7.8.2 Guardant Health Major Business
7.8.3 Guardant Health Measurable Residual Disease Testing Product and Services
7.8.4 Guardant Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Guardant Health Recent Developments/Updates
7.8.6 Guardant Health Competitive Strengths & Weaknesses
7.9 ICON plc
7.9.1 ICON plc Details
7.9.2 ICON plc Major Business
7.9.3 ICON plc Measurable Residual Disease Testing Product and Services
7.9.4 ICON plc Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 ICON plc Recent Developments/Updates
7.9.6 ICON plc Competitive Strengths & Weaknesses
7.10 Invivoscribe
7.10.1 Invivoscribe Details
7.10.2 Invivoscribe Major Business
7.10.3 Invivoscribe Measurable Residual Disease Testing Product and Services
7.10.4 Invivoscribe Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Invivoscribe Recent Developments/Updates
7.10.6 Invivoscribe Competitive Strengths & Weaknesses
7.11 Laboratory Corporation of America Holdings
7.11.1 Laboratory Corporation of America Holdings Details
7.11.2 Laboratory Corporation of America Holdings Major Business
7.11.3 Laboratory Corporation of America Holdings Measurable Residual Disease Testing Product and Services
7.11.4 Laboratory Corporation of America Holdings Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Laboratory Corporation of America Holdings Recent Developments/Updates
7.11.6 Laboratory Corporation of America Holdings Competitive Strengths & Weaknesses
7.12 Mission Bio
7.12.1 Mission Bio Details
7.12.2 Mission Bio Major Business
7.12.3 Mission Bio Measurable Residual Disease Testing Product and Services
7.12.4 Mission Bio Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Mission Bio Recent Developments/Updates
7.12.6 Mission Bio Competitive Strengths & Weaknesses
7.13 Natera, Inc.
7.13.1 Natera, Inc. Details
7.13.2 Natera, Inc. Major Business
7.13.3 Natera, Inc. Measurable Residual Disease Testing Product and Services
7.13.4 Natera, Inc. Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Natera, Inc. Recent Developments/Updates
7.13.6 Natera, Inc. Competitive Strengths & Weaknesses
7.14 NeoGenomics Laboratories
7.14.1 NeoGenomics Laboratories Details
7.14.2 NeoGenomics Laboratories Major Business
7.14.3 NeoGenomics Laboratories Measurable Residual Disease Testing Product and Services
7.14.4 NeoGenomics Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 NeoGenomics Laboratories Recent Developments/Updates
7.14.6 NeoGenomics Laboratories Competitive Strengths & Weaknesses
7.15 Opko Health
7.15.1 Opko Health Details
7.15.2 Opko Health Major Business
7.15.3 Opko Health Measurable Residual Disease Testing Product and Services
7.15.4 Opko Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Opko Health Recent Developments/Updates
7.15.6 Opko Health Competitive Strengths & Weaknesses
7.16 Quest Diagnostics Incorporated
7.16.1 Quest Diagnostics Incorporated Details
7.16.2 Quest Diagnostics Incorporated Major Business
7.16.3 Quest Diagnostics Incorporated Measurable Residual Disease Testing Product and Services
7.16.4 Quest Diagnostics Incorporated Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Quest Diagnostics Incorporated Recent Developments/Updates
7.16.6 Quest Diagnostics Incorporated Competitive Strengths & Weaknesses
7.17 Sysmex Corporation
7.17.1 Sysmex Corporation Details
7.17.2 Sysmex Corporation Major Business
7.17.3 Sysmex Corporation Measurable Residual Disease Testing Product and Services
7.17.4 Sysmex Corporation Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Sysmex Corporation Recent Developments/Updates
7.17.6 Sysmex Corporation Competitive Strengths & Weaknesses
7.18 Genetron Health
7.18.1 Genetron Health Details
7.18.2 Genetron Health Major Business
7.18.3 Genetron Health Measurable Residual Disease Testing Product and Services
7.18.4 Genetron Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023)
7.18.5 Genetron Health Recent Developments/Updates
7.18.6 Genetron Health Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Measurable Residual Disease Testing Industry Chain
8.2 Measurable Residual Disease Testing Upstream Analysis
8.3 Measurable Residual Disease Testing Midstream Analysis
8.4 Measurable Residual Disease Testing Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Measurable Residual Disease Testing Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Measurable Residual Disease Testing Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Measurable Residual Disease Testing Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Measurable Residual Disease Testing Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Measurable Residual Disease Testing Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Measurable Residual Disease Testing Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Measurable Residual Disease Testing Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Measurable Residual Disease Testing Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Measurable Residual Disease Testing Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Measurable Residual Disease Testing Players in 2022
Table 12. World Measurable Residual Disease Testing Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Measurable Residual Disease Testing Company Evaluation Quadrant
Table 14. Head Office of Key Measurable Residual Disease Testing Player
Table 15. Measurable Residual Disease Testing Market: Company Product Type Footprint
Table 16. Measurable Residual Disease Testing Market: Company Product Application Footprint
Table 17. Measurable Residual Disease Testing Mergers & Acquisitions Activity
Table 18. United States VS China Measurable Residual Disease Testing Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Measurable Residual Disease Testing Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Measurable Residual Disease Testing Companies, Headquarters (States, Country)
Table 21. United States Based Companies Measurable Residual Disease Testing Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Measurable Residual Disease Testing Revenue Market Share (2018-2023)
Table 23. China Based Measurable Residual Disease Testing Companies, Headquarters (Province, Country)
Table 24. China Based Companies Measurable Residual Disease Testing Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Measurable Residual Disease Testing Revenue Market Share (2018-2023)
Table 26. Rest of World Based Measurable Residual Disease Testing Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Measurable Residual Disease Testing Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Measurable Residual Disease Testing Revenue Market Share (2018-2023)
Table 29. World Measurable Residual Disease Testing Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Measurable Residual Disease Testing Market Size by Type (2018-2023) & (USD Million)
Table 31. World Measurable Residual Disease Testing Market Size by Type (2024-2029) & (USD Million)
Table 32. World Measurable Residual Disease Testing Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Measurable Residual Disease Testing Market Size by Application (2018-2023) & (USD Million)
Table 34. World Measurable Residual Disease Testing Market Size by Application (2024-2029) & (USD Million)
Table 35. Adaptive Biotechnologies Corporation Basic Information, Area Served and Competitors
Table 36. Adaptive Biotechnologies Corporation Major Business
Table 37. Adaptive Biotechnologies Corporation Measurable Residual Disease Testing Product and Services
Table 38. Adaptive Biotechnologies Corporation Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Adaptive Biotechnologies Corporation Recent Developments/Updates
Table 40. Adaptive Biotechnologies Corporation Competitive Strengths & Weaknesses
Table 41. ArcherDX, Inc. (Invitae Corporation) Basic Information, Area Served and Competitors
Table 42. ArcherDX, Inc. (Invitae Corporation) Major Business
Table 43. ArcherDX, Inc. (Invitae Corporation) Measurable Residual Disease Testing Product and Services
Table 44. ArcherDX, Inc. (Invitae Corporation) Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. ArcherDX, Inc. (Invitae Corporation) Recent Developments/Updates
Table 46. ArcherDX, Inc. (Invitae Corporation) Competitive Strengths & Weaknesses
Table 47. Asuragen Basic Information, Area Served and Competitors
Table 48. Asuragen Major Business
Table 49. Asuragen Measurable Residual Disease Testing Product and Services
Table 50. Asuragen Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Asuragen Recent Developments/Updates
Table 52. Asuragen Competitive Strengths & Weaknesses
Table 53. Arup Laboratories Basic Information, Area Served and Competitors
Table 54. Arup Laboratories Major Business
Table 55. Arup Laboratories Measurable Residual Disease Testing Product and Services
Table 56. Arup Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Arup Laboratories Recent Developments/Updates
Table 58. Arup Laboratories Competitive Strengths & Weaknesses
Table 59. Bio-Rad Laboratories Basic Information, Area Served and Competitors
Table 60. Bio-Rad Laboratories Major Business
Table 61. Bio-Rad Laboratories Measurable Residual Disease Testing Product and Services
Table 62. Bio-Rad Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Bio-Rad Laboratories Recent Developments/Updates
Table 64. Bio-Rad Laboratories Competitive Strengths & Weaknesses
Table 65. Cergentis B.V. Basic Information, Area Served and Competitors
Table 66. Cergentis B.V. Major Business
Table 67. Cergentis B.V. Measurable Residual Disease Testing Product and Services
Table 68. Cergentis B.V. Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Cergentis B.V. Recent Developments/Updates
Table 70. Cergentis B.V. Competitive Strengths & Weaknesses
Table 71. F. Hoffmann- La Roche Ltd Basic Information, Area Served and Competitors
Table 72. F. Hoffmann- La Roche Ltd Major Business
Table 73. F. Hoffmann- La Roche Ltd Measurable Residual Disease Testing Product and Services
Table 74. F. Hoffmann- La Roche Ltd Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. F. Hoffmann- La Roche Ltd Recent Developments/Updates
Table 76. F. Hoffmann- La Roche Ltd Competitive Strengths & Weaknesses
Table 77. Guardant Health Basic Information, Area Served and Competitors
Table 78. Guardant Health Major Business
Table 79. Guardant Health Measurable Residual Disease Testing Product and Services
Table 80. Guardant Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Guardant Health Recent Developments/Updates
Table 82. Guardant Health Competitive Strengths & Weaknesses
Table 83. ICON plc Basic Information, Area Served and Competitors
Table 84. ICON plc Major Business
Table 85. ICON plc Measurable Residual Disease Testing Product and Services
Table 86. ICON plc Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. ICON plc Recent Developments/Updates
Table 88. ICON plc Competitive Strengths & Weaknesses
Table 89. Invivoscribe Basic Information, Area Served and Competitors
Table 90. Invivoscribe Major Business
Table 91. Invivoscribe Measurable Residual Disease Testing Product and Services
Table 92. Invivoscribe Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Invivoscribe Recent Developments/Updates
Table 94. Invivoscribe Competitive Strengths & Weaknesses
Table 95. Laboratory Corporation of America Holdings Basic Information, Area Served and Competitors
Table 96. Laboratory Corporation of America Holdings Major Business
Table 97. Laboratory Corporation of America Holdings Measurable Residual Disease Testing Product and Services
Table 98. Laboratory Corporation of America Holdings Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Laboratory Corporation of America Holdings Recent Developments/Updates
Table 100. Laboratory Corporation of America Holdings Competitive Strengths & Weaknesses
Table 101. Mission Bio Basic Information, Area Served and Competitors
Table 102. Mission Bio Major Business
Table 103. Mission Bio Measurable Residual Disease Testing Product and Services
Table 104. Mission Bio Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Mission Bio Recent Developments/Updates
Table 106. Mission Bio Competitive Strengths & Weaknesses
Table 107. Natera, Inc. Basic Information, Area Served and Competitors
Table 108. Natera, Inc. Major Business
Table 109. Natera, Inc. Measurable Residual Disease Testing Product and Services
Table 110. Natera, Inc. Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Natera, Inc. Recent Developments/Updates
Table 112. Natera, Inc. Competitive Strengths & Weaknesses
Table 113. NeoGenomics Laboratories Basic Information, Area Served and Competitors
Table 114. NeoGenomics Laboratories Major Business
Table 115. NeoGenomics Laboratories Measurable Residual Disease Testing Product and Services
Table 116. NeoGenomics Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. NeoGenomics Laboratories Recent Developments/Updates
Table 118. NeoGenomics Laboratories Competitive Strengths & Weaknesses
Table 119. Opko Health Basic Information, Area Served and Competitors
Table 120. Opko Health Major Business
Table 121. Opko Health Measurable Residual Disease Testing Product and Services
Table 122. Opko Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Opko Health Recent Developments/Updates
Table 124. Opko Health Competitive Strengths & Weaknesses
Table 125. Quest Diagnostics Incorporated Basic Information, Area Served and Competitors
Table 126. Quest Diagnostics Incorporated Major Business
Table 127. Quest Diagnostics Incorporated Measurable Residual Disease Testing Product and Services
Table 128. Quest Diagnostics Incorporated Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Quest Diagnostics Incorporated Recent Developments/Updates
Table 130. Quest Diagnostics Incorporated Competitive Strengths & Weaknesses
Table 131. Sysmex Corporation Basic Information, Area Served and Competitors
Table 132. Sysmex Corporation Major Business
Table 133. Sysmex Corporation Measurable Residual Disease Testing Product and Services
Table 134. Sysmex Corporation Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 135. Sysmex Corporation Recent Developments/Updates
Table 136. Genetron Health Basic Information, Area Served and Competitors
Table 137. Genetron Health Major Business
Table 138. Genetron Health Measurable Residual Disease Testing Product and Services
Table 139. Genetron Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 140. Global Key Players of Measurable Residual Disease Testing Upstream (Raw Materials)
Table 141. Measurable Residual Disease Testing Typical Customers
Table 1. World Measurable Residual Disease Testing Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Measurable Residual Disease Testing Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Measurable Residual Disease Testing Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Measurable Residual Disease Testing Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Measurable Residual Disease Testing Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Measurable Residual Disease Testing Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Measurable Residual Disease Testing Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Measurable Residual Disease Testing Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Measurable Residual Disease Testing Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Measurable Residual Disease Testing Players in 2022
Table 12. World Measurable Residual Disease Testing Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Measurable Residual Disease Testing Company Evaluation Quadrant
Table 14. Head Office of Key Measurable Residual Disease Testing Player
Table 15. Measurable Residual Disease Testing Market: Company Product Type Footprint
Table 16. Measurable Residual Disease Testing Market: Company Product Application Footprint
Table 17. Measurable Residual Disease Testing Mergers & Acquisitions Activity
Table 18. United States VS China Measurable Residual Disease Testing Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Measurable Residual Disease Testing Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Measurable Residual Disease Testing Companies, Headquarters (States, Country)
Table 21. United States Based Companies Measurable Residual Disease Testing Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Measurable Residual Disease Testing Revenue Market Share (2018-2023)
Table 23. China Based Measurable Residual Disease Testing Companies, Headquarters (Province, Country)
Table 24. China Based Companies Measurable Residual Disease Testing Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Measurable Residual Disease Testing Revenue Market Share (2018-2023)
Table 26. Rest of World Based Measurable Residual Disease Testing Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Measurable Residual Disease Testing Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Measurable Residual Disease Testing Revenue Market Share (2018-2023)
Table 29. World Measurable Residual Disease Testing Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Measurable Residual Disease Testing Market Size by Type (2018-2023) & (USD Million)
Table 31. World Measurable Residual Disease Testing Market Size by Type (2024-2029) & (USD Million)
Table 32. World Measurable Residual Disease Testing Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Measurable Residual Disease Testing Market Size by Application (2018-2023) & (USD Million)
Table 34. World Measurable Residual Disease Testing Market Size by Application (2024-2029) & (USD Million)
Table 35. Adaptive Biotechnologies Corporation Basic Information, Area Served and Competitors
Table 36. Adaptive Biotechnologies Corporation Major Business
Table 37. Adaptive Biotechnologies Corporation Measurable Residual Disease Testing Product and Services
Table 38. Adaptive Biotechnologies Corporation Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Adaptive Biotechnologies Corporation Recent Developments/Updates
Table 40. Adaptive Biotechnologies Corporation Competitive Strengths & Weaknesses
Table 41. ArcherDX, Inc. (Invitae Corporation) Basic Information, Area Served and Competitors
Table 42. ArcherDX, Inc. (Invitae Corporation) Major Business
Table 43. ArcherDX, Inc. (Invitae Corporation) Measurable Residual Disease Testing Product and Services
Table 44. ArcherDX, Inc. (Invitae Corporation) Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. ArcherDX, Inc. (Invitae Corporation) Recent Developments/Updates
Table 46. ArcherDX, Inc. (Invitae Corporation) Competitive Strengths & Weaknesses
Table 47. Asuragen Basic Information, Area Served and Competitors
Table 48. Asuragen Major Business
Table 49. Asuragen Measurable Residual Disease Testing Product and Services
Table 50. Asuragen Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Asuragen Recent Developments/Updates
Table 52. Asuragen Competitive Strengths & Weaknesses
Table 53. Arup Laboratories Basic Information, Area Served and Competitors
Table 54. Arup Laboratories Major Business
Table 55. Arup Laboratories Measurable Residual Disease Testing Product and Services
Table 56. Arup Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Arup Laboratories Recent Developments/Updates
Table 58. Arup Laboratories Competitive Strengths & Weaknesses
Table 59. Bio-Rad Laboratories Basic Information, Area Served and Competitors
Table 60. Bio-Rad Laboratories Major Business
Table 61. Bio-Rad Laboratories Measurable Residual Disease Testing Product and Services
Table 62. Bio-Rad Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Bio-Rad Laboratories Recent Developments/Updates
Table 64. Bio-Rad Laboratories Competitive Strengths & Weaknesses
Table 65. Cergentis B.V. Basic Information, Area Served and Competitors
Table 66. Cergentis B.V. Major Business
Table 67. Cergentis B.V. Measurable Residual Disease Testing Product and Services
Table 68. Cergentis B.V. Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Cergentis B.V. Recent Developments/Updates
Table 70. Cergentis B.V. Competitive Strengths & Weaknesses
Table 71. F. Hoffmann- La Roche Ltd Basic Information, Area Served and Competitors
Table 72. F. Hoffmann- La Roche Ltd Major Business
Table 73. F. Hoffmann- La Roche Ltd Measurable Residual Disease Testing Product and Services
Table 74. F. Hoffmann- La Roche Ltd Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. F. Hoffmann- La Roche Ltd Recent Developments/Updates
Table 76. F. Hoffmann- La Roche Ltd Competitive Strengths & Weaknesses
Table 77. Guardant Health Basic Information, Area Served and Competitors
Table 78. Guardant Health Major Business
Table 79. Guardant Health Measurable Residual Disease Testing Product and Services
Table 80. Guardant Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Guardant Health Recent Developments/Updates
Table 82. Guardant Health Competitive Strengths & Weaknesses
Table 83. ICON plc Basic Information, Area Served and Competitors
Table 84. ICON plc Major Business
Table 85. ICON plc Measurable Residual Disease Testing Product and Services
Table 86. ICON plc Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. ICON plc Recent Developments/Updates
Table 88. ICON plc Competitive Strengths & Weaknesses
Table 89. Invivoscribe Basic Information, Area Served and Competitors
Table 90. Invivoscribe Major Business
Table 91. Invivoscribe Measurable Residual Disease Testing Product and Services
Table 92. Invivoscribe Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Invivoscribe Recent Developments/Updates
Table 94. Invivoscribe Competitive Strengths & Weaknesses
Table 95. Laboratory Corporation of America Holdings Basic Information, Area Served and Competitors
Table 96. Laboratory Corporation of America Holdings Major Business
Table 97. Laboratory Corporation of America Holdings Measurable Residual Disease Testing Product and Services
Table 98. Laboratory Corporation of America Holdings Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Laboratory Corporation of America Holdings Recent Developments/Updates
Table 100. Laboratory Corporation of America Holdings Competitive Strengths & Weaknesses
Table 101. Mission Bio Basic Information, Area Served and Competitors
Table 102. Mission Bio Major Business
Table 103. Mission Bio Measurable Residual Disease Testing Product and Services
Table 104. Mission Bio Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Mission Bio Recent Developments/Updates
Table 106. Mission Bio Competitive Strengths & Weaknesses
Table 107. Natera, Inc. Basic Information, Area Served and Competitors
Table 108. Natera, Inc. Major Business
Table 109. Natera, Inc. Measurable Residual Disease Testing Product and Services
Table 110. Natera, Inc. Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Natera, Inc. Recent Developments/Updates
Table 112. Natera, Inc. Competitive Strengths & Weaknesses
Table 113. NeoGenomics Laboratories Basic Information, Area Served and Competitors
Table 114. NeoGenomics Laboratories Major Business
Table 115. NeoGenomics Laboratories Measurable Residual Disease Testing Product and Services
Table 116. NeoGenomics Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. NeoGenomics Laboratories Recent Developments/Updates
Table 118. NeoGenomics Laboratories Competitive Strengths & Weaknesses
Table 119. Opko Health Basic Information, Area Served and Competitors
Table 120. Opko Health Major Business
Table 121. Opko Health Measurable Residual Disease Testing Product and Services
Table 122. Opko Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Opko Health Recent Developments/Updates
Table 124. Opko Health Competitive Strengths & Weaknesses
Table 125. Quest Diagnostics Incorporated Basic Information, Area Served and Competitors
Table 126. Quest Diagnostics Incorporated Major Business
Table 127. Quest Diagnostics Incorporated Measurable Residual Disease Testing Product and Services
Table 128. Quest Diagnostics Incorporated Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Quest Diagnostics Incorporated Recent Developments/Updates
Table 130. Quest Diagnostics Incorporated Competitive Strengths & Weaknesses
Table 131. Sysmex Corporation Basic Information, Area Served and Competitors
Table 132. Sysmex Corporation Major Business
Table 133. Sysmex Corporation Measurable Residual Disease Testing Product and Services
Table 134. Sysmex Corporation Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 135. Sysmex Corporation Recent Developments/Updates
Table 136. Genetron Health Basic Information, Area Served and Competitors
Table 137. Genetron Health Major Business
Table 138. Genetron Health Measurable Residual Disease Testing Product and Services
Table 139. Genetron Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 140. Global Key Players of Measurable Residual Disease Testing Upstream (Raw Materials)
Table 141. Measurable Residual Disease Testing Typical Customers
LIST OF FIGURES
Figure 1. Measurable Residual Disease Testing Picture
Figure 2. World Measurable Residual Disease Testing Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Measurable Residual Disease Testing Total Market Size (2018-2029) & (USD Million)
Figure 4. World Measurable Residual Disease Testing Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Measurable Residual Disease Testing Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Measurable Residual Disease Testing Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Measurable Residual Disease Testing Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Measurable Residual Disease Testing Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Measurable Residual Disease Testing Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Measurable Residual Disease Testing Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Measurable Residual Disease Testing Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Measurable Residual Disease Testing Revenue (2018-2029) & (USD Million)
Figure 13. Measurable Residual Disease Testing Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Measurable Residual Disease Testing Consumption Value (2018-2029) & (USD Million)
Figure 16. World Measurable Residual Disease Testing Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Measurable Residual Disease Testing Consumption Value (2018-2029) & (USD Million)
Figure 18. China Measurable Residual Disease Testing Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Measurable Residual Disease Testing Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Measurable Residual Disease Testing Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Measurable Residual Disease Testing Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Measurable Residual Disease Testing Consumption Value (2018-2029) & (USD Million)
Figure 23. India Measurable Residual Disease Testing Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Measurable Residual Disease Testing by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Measurable Residual Disease Testing Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Measurable Residual Disease Testing Markets in 2022
Figure 27. United States VS China: Measurable Residual Disease Testing Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Measurable Residual Disease Testing Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Measurable Residual Disease Testing Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Measurable Residual Disease Testing Market Size Market Share by Type in 2022
Figure 31. Flow Cytometry
Figure 32. Polymerase Chain Reaction (PCR)
Figure 33. Next-Generation Sequencing (NGS)
Figure 34. Other
Figure 35. World Measurable Residual Disease Testing Market Size Market Share by Type (2018-2029)
Figure 36. World Measurable Residual Disease Testing Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 37. World Measurable Residual Disease Testing Market Size Market Share by Application in 2022
Figure 38. Hematological Malignancies
Figure 39. Leukemia
Figure 40. Lymphoma
Figure 41. Solid Tumors
Figure 42. Other
Figure 43. Measurable Residual Disease Testing Industrial Chain
Figure 44. Methodology
Figure 45. Research Process and Data Source
Figure 1. Measurable Residual Disease Testing Picture
Figure 2. World Measurable Residual Disease Testing Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Measurable Residual Disease Testing Total Market Size (2018-2029) & (USD Million)
Figure 4. World Measurable Residual Disease Testing Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Measurable Residual Disease Testing Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Measurable Residual Disease Testing Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Measurable Residual Disease Testing Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Measurable Residual Disease Testing Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Measurable Residual Disease Testing Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Measurable Residual Disease Testing Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Measurable Residual Disease Testing Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Measurable Residual Disease Testing Revenue (2018-2029) & (USD Million)
Figure 13. Measurable Residual Disease Testing Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Measurable Residual Disease Testing Consumption Value (2018-2029) & (USD Million)
Figure 16. World Measurable Residual Disease Testing Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Measurable Residual Disease Testing Consumption Value (2018-2029) & (USD Million)
Figure 18. China Measurable Residual Disease Testing Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Measurable Residual Disease Testing Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Measurable Residual Disease Testing Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Measurable Residual Disease Testing Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Measurable Residual Disease Testing Consumption Value (2018-2029) & (USD Million)
Figure 23. India Measurable Residual Disease Testing Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Measurable Residual Disease Testing by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Measurable Residual Disease Testing Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Measurable Residual Disease Testing Markets in 2022
Figure 27. United States VS China: Measurable Residual Disease Testing Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Measurable Residual Disease Testing Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Measurable Residual Disease Testing Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Measurable Residual Disease Testing Market Size Market Share by Type in 2022
Figure 31. Flow Cytometry
Figure 32. Polymerase Chain Reaction (PCR)
Figure 33. Next-Generation Sequencing (NGS)
Figure 34. Other
Figure 35. World Measurable Residual Disease Testing Market Size Market Share by Type (2018-2029)
Figure 36. World Measurable Residual Disease Testing Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 37. World Measurable Residual Disease Testing Market Size Market Share by Application in 2022
Figure 38. Hematological Malignancies
Figure 39. Leukemia
Figure 40. Lymphoma
Figure 41. Solid Tumors
Figure 42. Other
Figure 43. Measurable Residual Disease Testing Industrial Chain
Figure 44. Methodology
Figure 45. Research Process and Data Source
